Literature DB >> 23347103

Prevalence of MED12 mutations in uterine and extrauterine smooth muscle tumours.

Akiko Matsubara1, Shigeki Sekine, Masayuki Yoshida, Akihiko Yoshida, Hirokazu Taniguchi, Ryoji Kushima, Hitoshi Tsuda, Yae Kanai.   

Abstract

AIMS: To determine the prevalence of MED12 mutations in smooth muscle tumours of different organs. METHODS AND
RESULTS: A total of 142 smooth muscle tumours of the uterus, gastrointestinal tract, retroperitoneum and soft tissue were analysed for MED12 mutations using Sanger sequencing. Among the uterine tumours that were examined, MED12 mutations were identified in 36 of 45 conventional leiomyomas (80%), two of six cellular leiomyomas (33%), one of four bizarre leiomyomas (25%), none of four lipoleiomyomas (0%), and two of 12 leiomyosarcomas (17%). The two MED12-mutated leiomyosarcomas were associated with benign leiomyomatous components that also harboured MED12 mutations identical to those in the respective leiomyosarcomatous components. None of the extrauterine smooth muscle tumours, including the leiomyomas, leiomyosarcomas, and angioleiomyomas, had MED12 mutations.
CONCLUSIONS: Among uterine smooth muscle tumours, MED12 mutations are frequently present in conventional leiomyomas, but are significantly less common in histological variants of leiomyoma and leiomyosarcoma. In contrast to uterine lesions, none of the extrauterine smooth muscle tumours had MED12 mutations.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23347103     DOI: 10.1111/his.12039

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  26 in total

Review 1.  MED12 related disorders.

Authors:  John M Graham; Charles E Schwartz
Journal:  Am J Med Genet A       Date:  2013-10-10       Impact factor: 2.802

2.  Somatic mutational analysis of MED12 exon 2 in uterine leiomyomas of Iranian women.

Authors:  Shirin Shahbazi; Neda Fatahi; Soheila Amini-Moghaddam
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

3.  MED12 somatic mutations in fibroadenomas and phyllodes tumours of the breast.

Authors:  Salvatore Piscuoglio; Melissa Murray; Nicola Fusco; Caterina Marchiò; Florence L Loo; Luciano G Martelotto; Anne M Schultheis; Muzaffar Akram; Britta Weigelt; Edi Brogi; Jorge S Reis-Filho
Journal:  Histopathology       Date:  2015-05-24       Impact factor: 5.087

Review 4.  Epidemiological and genetic clues for molecular mechanisms involved in uterine leiomyoma development and growth.

Authors:  Arno E Commandeur; Aaron K Styer; Jose M Teixeira
Journal:  Hum Reprod Update       Date:  2015-07-03       Impact factor: 15.610

Review 5.  Practical issues in uterine pathology from banal to bewildering: the remarkable spectrum of smooth muscle neoplasia.

Authors:  Esther Oliva
Journal:  Mod Pathol       Date:  2016-01       Impact factor: 7.842

Review 6.  Tissue-specific stem cells in the myometrium and tumor-initiating cells in leiomyoma.

Authors:  Masanori Ono; Serdar E Bulun; Tetsuo Maruyama
Journal:  Biol Reprod       Date:  2014-11-05       Impact factor: 4.285

Review 7.  Mediator kinase module and human tumorigenesis.

Authors:  Alison D Clark; Marieke Oldenbroek; Thomas G Boyer
Journal:  Crit Rev Biochem Mol Biol       Date:  2015-07-16       Impact factor: 8.250

8.  High-resolution melting analysis of MED12 mutations in uterine leiomyomas in Chinese patients.

Authors:  Hua Wang; Jun Ye; Hua Qian; Ruifang Zhou; Jun Jiang; Lihua Ye
Journal:  Genet Test Mol Biomarkers       Date:  2015-01-23

Review 9.  Reasons to Reconsider Risk Associated With Power Morcellation of Uterine Fibroids.

Authors:  Burkhard Helmke; Joern Bullerdiek; Carsten Holzmann; Wolfgang Kuepker; Birgit Rommel
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

10.  Frequency of MED12 Mutation in Relation to Tumor and Patient's Clinical Characteristics: a Meta-analysis.

Authors:  Chao He; William Nelson; Hui Li; Ya-Dong Xu; Xue-Jiao Dai; Ying-Xiong Wang; Yu-Bin Ding; Yan-Ping Li; Tian Li
Journal:  Reprod Sci       Date:  2021-02-10       Impact factor: 3.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.